Raymond James added Relay Therapeutics to the firm’s Analyst Current Favorites list. The list contains the current favorite stock ideas from the firm’s equity analysts. An analyst may only have one “buy” idea on the list at any given time.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Relay well-positioned to generate significant value with RLY-2608, says Stifel
- Relay Therapeutics price target raised to $19 from $18 at H.C. Wainwright
- Relay Therapeutics 28.6M share Secondary priced at $7.00
- Oracle reports Q1 beat, EU says Apple must pay: Morning Buzz
- Alphabet, Meta initiated: Wall Street’s top analyst calls